-
Something wrong with this record ?
A rare epidermal growth factor receptor (EGFR) gene mutation in small cell lung carcinoma patients
CC. Hwang, TY. Hsieh, KY. Yeh, TP. Chen, CC. Hua, LC. Chang, JR. Chen
Language English Country Czech Republic
Document type Case Reports, Journal Article
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
PubMed
35228756
DOI
10.5507/bp.2022.007
Knihovny.cz E-resources
- MeSH
- ErbB Receptors genetics MeSH
- Formaldehyde MeSH
- In Situ Hybridization, Fluorescence MeSH
- Humans MeSH
- Small Cell Lung Carcinoma * genetics MeSH
- Mutation MeSH
- DNA Mutational Analysis methods MeSH
- Lung Neoplasms * diagnosis MeSH
- Carcinoma, Non-Small-Cell Lung * diagnosis MeSH
- Paraffin MeSH
- Retrospective Studies MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
AIM: Activating mutations in the epidermal growth factor receptor (EGFR) are predominantly detected in pulmonary adenocarcinoma and have been reported in small cell lung cancer (SCLC) for decades. This retrospective single-center study aimed to determine the frequency and types of EGFR mutations in SCLC in Taiwan. METHODS: This study comprises a consecutive cohort of 161 patients histologically diagnosed with SCLC between January 1992 and August 2014 at the Department of Pathology in Keelung Chang Gung Memorial Hospital, Taiwan. Archived formalin-fixed paraffin-embedded sections from 71 patients were eligible for molecular analysis. EGFR mutation analysis was performed using a fully-automated IdyllaTM EGFR Mutation Test and confirmed a comparable result through Qiagen Therascreen® EGFR RGQ PCR. In addition, EGFR gene copy number was assessed in EGFR-mutated tumors by fluorescence in situ hybridization (FISH). RESULTS: Mutational status of the EGFR gene was successfully analyzed in 63 specimens by both IdyllaTM and Qiagen platforms. Both methods detected L858R point mutation in exon 21 in an 81-year-old female and a 47-year-old male non-smoker. Both tumors show no concurrent EGFR gene amplification. The overall agreement between results obtained with the IdyllaTM EGFR Mutation Test and Qiagen Therascreen® EGFR RGQ PCR was 100% Conclusions. Our results showed that EGFR mutation is a rare mutation type in a consecutive series of de novo SCLC. Furthermore, the performance of IdyllaTM EGFR Mutation Test and Qiagen Therascreen® EGFR RGQ PCR on archived paraffin sections of limited quantities is available with the high agreement of results.
College of Medicine Chang Gung University Kwei Shan Taoyuan Taiwan
Department of Pathology Keelung Chang Gung Memorial Hospital Keelung Taiwan
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22022907
- 003
- CZ-PrNML
- 005
- 20230118155302.0
- 007
- ta
- 008
- 221007s2022 xr da f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2022.007 $2 doi
- 035 __
- $a (PubMed)35228756
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Hwang, Cheng-Cheng $u Department of Pathology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan $u College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan
- 245 12
- $a A rare epidermal growth factor receptor (EGFR) gene mutation in small cell lung carcinoma patients / $c CC. Hwang, TY. Hsieh, KY. Yeh, TP. Chen, CC. Hua, LC. Chang, JR. Chen
- 520 9_
- $a AIM: Activating mutations in the epidermal growth factor receptor (EGFR) are predominantly detected in pulmonary adenocarcinoma and have been reported in small cell lung cancer (SCLC) for decades. This retrospective single-center study aimed to determine the frequency and types of EGFR mutations in SCLC in Taiwan. METHODS: This study comprises a consecutive cohort of 161 patients histologically diagnosed with SCLC between January 1992 and August 2014 at the Department of Pathology in Keelung Chang Gung Memorial Hospital, Taiwan. Archived formalin-fixed paraffin-embedded sections from 71 patients were eligible for molecular analysis. EGFR mutation analysis was performed using a fully-automated IdyllaTM EGFR Mutation Test and confirmed a comparable result through Qiagen Therascreen® EGFR RGQ PCR. In addition, EGFR gene copy number was assessed in EGFR-mutated tumors by fluorescence in situ hybridization (FISH). RESULTS: Mutational status of the EGFR gene was successfully analyzed in 63 specimens by both IdyllaTM and Qiagen platforms. Both methods detected L858R point mutation in exon 21 in an 81-year-old female and a 47-year-old male non-smoker. Both tumors show no concurrent EGFR gene amplification. The overall agreement between results obtained with the IdyllaTM EGFR Mutation Test and Qiagen Therascreen® EGFR RGQ PCR was 100% Conclusions. Our results showed that EGFR mutation is a rare mutation type in a consecutive series of de novo SCLC. Furthermore, the performance of IdyllaTM EGFR Mutation Test and Qiagen Therascreen® EGFR RGQ PCR on archived paraffin sections of limited quantities is available with the high agreement of results.
- 650 12
- $a nemalobuněčný karcinom plic $x diagnóza $7 D002289
- 650 _2
- $a mutační analýza DNA $x metody $7 D004252
- 650 _2
- $a erbB receptory $x genetika $7 D066246
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a formaldehyd $7 D005557
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hybridizace in situ fluorescenční $7 D017404
- 650 12
- $a nádory plic $x diagnóza $7 D008175
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a parafín $7 D010232
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a malobuněčný karcinom plic $x genetika $7 D055752
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Hsieh, Tsan-Yu $u Department of Pathology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan $u College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan
- 700 1_
- $a Yeh, Kun-Yang $u College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan $u Department of Oncology and Hematology, Division of Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan
- 700 1_
- $a Chen, Tzu-Ping $u College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan $u Department of Thoracic and Cardiovascular Surgery, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan
- 700 1_
- $a Hua, Chung-Ching $u College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan $u Department of Thoracic Medicine, Division of Medicine, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan
- 700 1_
- $a Chang, Liang-Che $u Department of Pathology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan $u College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan
- 700 1_
- $a Chen, Jim-Ray $u Department of Pathology, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan $u College of Medicine, Chang Gung University, Kwei-Shan, Taoyuan, Taiwan
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 166, č. 3 (2022), s. 274-279
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35228756 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y p $z 0
- 990 __
- $a 20221007 $b ABA008
- 991 __
- $a 20230118155256 $b ABA008
- 999 __
- $a ok $b bmc $g 1885613 $s 1174193
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 166 $c 3 $d 274-279 $e 20220218 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK138 $a Pubmed-20221007
